Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

45results about How to "Small systemic side effects" patented technology

Medicament coating material and preparation method

The invention relates to the field of vascular tissue engineering, in particular to a medicament coating material which can be used in vascular tissue engineering and intervened in a stent and a preparation method. The coating material has the characteristics of degradability and an effect on promoting the growth of endothelial cells and inhibiting platelet adhesion. The coating material takes a polymer material which has good biocompatibility as a medicament carrier, and takes an effective extracts such as ferulic acid and derivatives thereof of a traditional Chinese medicament angelica sinensis. The preparation method has the following processes of: fully dissolving the medicament carrier and a medicament with a solvent; and using after mixing uniformly by ultrasonic sound. The medicament coating material can be prepared by a solution pouring method, wherein uniformly dissolved solution is poured in glass ware; volatilizing the solvent for 24 hours at the temperature of between 20 and 25 DEG C in vacuum to form a film; continuing heating for volatilizing the solvent thoroughly for 48 hours; and sterilizing for later use. The coating material has the effects on inhibiting the platelet adhesion and prompting the growth of endothelial cells, and can be used in the field of vascular tissue engineering and intervened in a degradable medicament coating on a stent surface.
Owner:INST OF METAL RESEARCH - CHINESE ACAD OF SCI

Albumin nanoparticles capable of double-stage oxygen carrying and preparation method and application thereof

The invention belongs to the field of radiotherapy sensibilization medicines, and relates to albumin nanoparticles capable of double-stage oxygen carrying and a preparation method and application thereof. The albumin nanoparticles are mainly prepared from albumin, perfluoro-carbon and catalase, the particle size of the albumin nanoparticles is even, the property is stable, the biosecurity is good,and the problem of radiotherapy resisting of solid tumors can be solved. Experimental results show that the nanoparticles can target the tumors and improve tumor hypoxia by means of double-stage oxygen carrying, for specific performance of double-stage oxygen carrying of the nanoparticles, the high-oxygen-carrying perfluoro-carbon directly supplies oxygen (first stage oxygen carrying) to the hypoxic tumors directly through oxygen concentration gradient difference, meanwhile, the catalase conducts catalytic hydrolysis on high-concentration hydrogen peroxide on the tumor portions to generate oxygen for indirect oxygen carrying (second stage oxygen carrying), through synergism of first stage oxygen carrying and second stage oxygen carrying, a tumor hypoxia microenvironment is reversed, and effective sensibilization is conducted on oxygen-dependent tumor radiotherapy.
Owner:南京从一医药科技有限公司

Preparation method of drug microcarrier for acquired deafness based on microfluidic technology

The invention relates to a preparation method of a drug microcarrier for acquired deafness based on a microfluidic technology, which comprises the following steps of: controlling the generation of internal and external two-phase fluid by utilizing the micro-fluidic technology; the internal and external two-phase fluid generation process comprises the following steps: S1, preparing micron-scale liquid drops capable of being used for tympanic injection by utilizing shearing force and interfacial tension between two-phase fluids which are mutually insoluble, and in-situ entrapping hearing protective drugs and an auxiliary agent for increasing the permeability of a round window membrane; and S2, solidifying the liquid drops through polymerization reaction to form the drug microcarrier. Compared with the prior art, the prepared medicine microcarrier can be used for treating acquired deafness through tympanic injection, the middle ear cavity is filled with the medicine microcarrier through tympanic injection, the medicine is slowly released through natural degradation of the microcarrier and enters the inner ear through the round window membrane, and the effect of treating acquired deafness is achieved; the drug microcarrier has the advantages of small side effect and injury, lasting effect, obvious effect, simple operation and the like.
Owner:FUDAN UNIV

Chitosan-oligosaccharide-modified self-carrying type carrier-free nasal cavity nano preparation brain-targeted delivery system and preparation method thereof

ActiveCN109730966ANo degradabilityCumulative toxicity NonePowder deliveryNervous disorderNasal cavityFreeze-drying
The invention discloses a chitosan-oligosaccharide-modified self-carrying type carrier-free nasal cavity nano preparation brain-targeted delivery system and a preparation method thereof. The system includes hydrophobic micro-molecule drugs, polyethylene glycol derivatives and chitosan oligosaccharide which have a neuroprotective effect. The invention also provides a preparation method of the nasalcavity nano preparation brain-targeted delivery system. The preparation method includes the steps of 1, preparing nano-particle freeze-dried powder; 2, stirring the freeze-dried powder and chitosan oligosaccharide in isotonic normal saline before use to form a nasal cavity preparation with good membrane permeability. The system is simple in preparation method and can improve the hydrophobicity ofthe micro-molecule drugs, reduce the toxicity and enhance the ne neuroprotective effect. The system is free of carriers, biodegradation problems and accumulation of toxin. The drug carrying rate reaches 25 percent or above, a permeable membrane has good absorption performance after being modified by chitosan oligosaccharide, and the drugs are delivered into the brain with high targeting property.The application modes of the dosage form include nasal dripping, spray and the like, the operation is simple, convenience is provided for patients who have taken the drugs for a long time, and the system has a good application prospect in the aspect of treating nervous system diseases.
Owner:NASAL PHYTO SZ PHARMA TECH CO LTD

Application of exenatide to preparation of medicines for treating ocular ischemia diseases and improving ocular blood circulation in eye drip way

The invention relates to the technical field of medicines, in particular to application of exenatide to preparation of medicines for treating ocular ischemia diseases and improving ocular blood circulation in an eye drip way. The exenatide can be used for treating the ocular ischemia diseases such as onset of acute glaucoma and improving the ocular blood circulation . According to the applicationdisclosed by the invention, through building an acute ischemia reperfusion model and simulating damage of the onset of the acute glaucoma, findings prove that an eye drop preparation of Exendin-4 canimprove a retinal vascular endothelial function, dilating retinal capillary and recovering fundus blood circulation, so that the damage to the fundus blood supply caused by the ocular ischemia diseases such as acute glaucoma can be effectively alleviated, and simultaneously, the findings prove that a new medicine dosage form (eye drop preparation) can achieve an effective local action under the premise of avoiding systemic action. The exenatide disclosed by the invention can be used for treating deficiency of the fundus blood supply such as the acute glaucoma, retinopathy of prematurity and retinal vascular occlusion diseases, and thus, the visual function is saved.
Owner:EYE & ENT HOSPITAL SHANGHAI MEDICAL SCHOOL FUDAN UNIV

Preparation method of double-gene time sequence sustained-release tissue engineering scaffold material

The invention discloses a preparation method of a double-gene time sequence sustained-release tissue engineering scaffold material. The preparation method comprises the following steps: firstly, encapsulating plasmid containing IGF-I by virtue of a sustained-release material which is relatively high in molecular weight, so that sustained-release microspheres are prepared; and preparing the three-dimensional porous tissue engineering material from the microspheres, PLGA which is relatively low in molecular weight and plasmid containing BMP-2 by virtue of a supercritical CO2 and particulate leaching method. As the material is implanted into a body, a main body material, which is relatively low in molecular weight, around the BMP-2 plasmid which is not encapsulated in sustained-release microspheres is degraded firstly, and the BMP-2 plasmid is released firstly; while the IGF-I plasmid, which is encapsulated in the material, which is relatively high in molecular weight, is delayed in release, so that an effect that two target genes are released in a certain order. According to the material, cell factors can be subjected to time sequence expression in a mode of simulating a physiological process of tissue repair, so that the material is more conducive to tissue regeneration and systemic side effects are reduced; a gene product can achieve local continuous release; and a local therapeutic effect can be enhanced to the greatest extent.
Owner:温州医科大学附属口腔医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products